International Reference Pricing: How Countries Set Generic Drug Prices

Mar, 8 2026

When you buy a generic drug in Germany, France, or Spain, you might assume the price is set based on local costs, competition, or manufacturing expenses. But in most cases, it’s not. Instead, governments look to other countries to decide how much to pay. This is called international reference pricing-a system where a nation’s generic drug prices are tied to what other countries charge. It’s not a theory. It’s how 28 of 32 European countries actually control generic medicine costs today.

How International Reference Pricing Works for Generics

International reference pricing (IRP) doesn’t mean copying the lowest price in the world. It’s more like a smart averaging system. Countries pick a group of similar nations-usually 5 to 7-and look at what those countries charge for the exact same generic drug. Then they set their own reimbursement price based on the median or average of that group. For example, if Germany, France, Italy, Spain, and the Netherlands all charge between €0.20 and €0.40 for a 10mg tablet of atorvastatin, a country like Portugal might set its reimbursement at €0.32-the median price.

This approach works because generic drugs are identical in active ingredients, dosage, and effectiveness. A 10mg lisinopril tablet from a manufacturer in India is the same as one made in Germany. So why should one country pay 5 times more? IRP forces price alignment.

But here’s the twist: most European countries don’t use external reference pricing (comparing prices across borders) for generics. They use internal reference pricing. That means they group all interchangeable generics into a single basket-say, all 10mg lisinopril tablets-and then set one reimbursement price for the whole group. The lowest-priced product in that group gets full reimbursement. Others get less. If you’re a manufacturer and your tablet costs €0.40 but the lowest is €0.25, you’ll only get reimbursed €0.25. That pushes you to lower your price or lose market share.

Which Countries Use It-and How Differently?

Not every country plays by the same rules. In Germany, the system is called AMNOG. Since 2011, they’ve grouped generics into therapeutic classes and set reimbursement at the lowest price in the group plus a 3% margin. This keeps prices low but gives manufacturers a tiny incentive to stay in the market.

The Netherlands goes further. They combine IRP with mandatory discounts and tendering. When a generic drug is up for renewal, the government opens a competitive bid. The lowest bidder gets exclusive reimbursement rights. This has driven Dutch generic prices down to 65-85% below originator drugs.

Switzerland takes a hybrid approach. Their reference price for generics is two-thirds of the average international price and one-third based on domestic prices. This prevents them from being dragged down too far by low-cost countries while still keeping prices reasonable.

Meanwhile, the United States doesn’t use IRP at the federal level. Medicaid programs in a few states like Colorado have experimented with it, achieving 12-15% savings on generic drugs. But overall, U.S. drug pricing remains fragmented and largely market-driven.

Canada is another outlier. Their federal agency, the PMPRB, uses IRP only for patented drugs. For generics? Each province runs its own tendering system. Ontario and Quebec bid for bulk discounts, and prices vary widely between provinces.

Why It Works-And Why It Fails

The biggest win from IRP? Cost savings. Countries using IRP for generics have, on average, 25-40% lower prices than those that don’t. In France, after adopting dynamic reference pricing in 2023 (which adjusts prices quarterly based on market shifts), they saved an extra 8.2% in just six months.

But there’s a dark side. When prices are cut too aggressively, manufacturers walk away. In Portugal, 22 generic products disappeared from the market in 2019 because the reimbursement price didn’t cover production costs. In Greece during its financial crisis, 37% of generics faced shortages because prices were slashed too fast.

Another problem: quality perception. A 2021 OECD survey found that 34% of European patients worried about differences in quality between the cheapest, reference-priced generic and more expensive versions-even though they’re chemically identical. Pharmacists in Spain report that 63% of them have seen shortages of the lowest-priced product, forcing substitutions that patients don’t always trust.

And then there’s the innovation gap. Complex generics-like inhalers, injectables, or transdermal patches-cost nearly as much to develop as new drugs. But IRP doesn’t account for that. A 2020 FDA study showed a 17% drop in new complex generic applications in countries with strict IRP. Why invest millions to make a hard-to-copy generic if you’ll be forced to sell it for pennies?

Pharmacist holding two generic pills with different prices, under a sign indicating reimbursement at the lowest price.

How Countries Manage the Risks

Smart systems have learned from mistakes. The European Commission now recommends using 5-7 reference countries, not more. Studies show that using over 10 countries leads to diminishing returns: price reductions drop to 31%, but shortages jump 12%.

Germany’s Federal Joint Committee defines 1,247 reference groups for generics. Each group includes similar products, but they’re carefully curated. They don’t mix simple tablets with complex injectables. That’s key. Mixing apples and oranges in a reference basket leads to unfair pricing.

Some countries now build in flexibility. France’s quarterly updates respond to real-time price changes. The EU’s new European Reference Pricing Platform, launched in April 2023, is testing shared data between 7 countries for 15 key generics. The goal? More transparency, fewer surprises.

And manufacturers? They’ve adapted. Teva says IRP caused a 9% revenue drop in Europe, but volume grew 15%. Sandoz says well-designed systems helped them expand market share in 18 countries. The message: if you’re efficient, you can still profit-even under IRP.

The Future of Generic Drug Pricing

By 2027, IQVIA predicts 65% of European generic prices will be set by reference systems-up from 58% in 2022. But the trend isn’t just about price. It’s shifting toward value-based pricing.

Imagine a system where not all generics are treated the same. A simple aspirin tablet? Sure, base price on the cheapest. But a complex generic inhaler that requires advanced manufacturing? Maybe it gets a higher reference price. The OECD is already pushing for tiered reference groups based on therapeutic importance and manufacturing complexity.

Also, countries are starting to track more than just price. They’re asking: Is the product consistently available? Are there quality complaints? Are patients switching because of price-or because they’re forced to?

The goal isn’t to make generics as cheap as possible. It’s to make them affordable, reliable, and sustainable. Because if no one makes them, the price doesn’t matter.

Factory conveyor belt with pills labeled by countries, one broken pill labeled 'Out of Stock' beside a price balance scale.

What This Means for Patients and Providers

For patients, IRP means lower out-of-pocket costs. In countries with strong systems, generic substitution rates have jumped from 52% in 2010 to 89% in 2022 in Spain alone. That’s more access, more savings.

But it also means less choice. If your doctor prescribes a brand you like, and the system only reimburses the cheapest version, you might have to switch-even if you’re comfortable with your current one.

For pharmacists, IRP creates administrative headaches. They need to track which products are in which reference group, which ones are eligible for substitution, and which ones are out of stock. In Spain, maintaining the IRP system requires 15 full-time staff.

For prescribers, it means learning new rules. In 22 European countries, if a generic is 20% cheaper than the branded version, doctors are required to prescribe the generic unless they write a special note. It’s not about preference anymore. It’s about policy.

Final Thoughts: A Tool, Not a Fix-All

International reference pricing isn’t perfect. It can cause shortages. It can discourage innovation. It can erode trust if patients feel they’re getting the "cheap" version.

But it works. It’s the reason why a month’s supply of metformin costs €1.20 in Germany and €12 in the U.S. It’s why countries with IRP spend less on generics-and still get the same clinical outcomes.

The future won’t be about abandoning IRP. It’ll be about refining it. Tiered baskets. Dynamic updates. Better data. More transparency. And above all-recognizing that not all generics are created equal.

What countries use international reference pricing for generics?

28 of 32 European countries use some form of international reference pricing (IRP) for generic medicines. Most of Western Europe-including Germany, France, Italy, Spain, the Netherlands, and Portugal-rely on it. Eastern European countries like Romania and Bulgaria also use IRP, often referencing Austria, Germany, and the Netherlands. Outside Europe, Canada and Switzerland use modified versions, while the U.S. does not use IRP at the federal level, though some states like Colorado have tested it for Medicaid.

How is the reference price calculated for generics?

Most countries use the median or average price of a basket of 5-7 reference countries, not the lowest price. For example, if a generic drug costs €0.20, €0.28, €0.30, €0.35, and €0.40 in five reference countries, the median is €0.30, and that becomes the reimbursement benchmark. Some countries, like Germany, add a small margin (3%) to the lowest price in the group. Others, like the Netherlands, combine IRP with competitive tendering to drive prices even lower.

Does international reference pricing lower drug quality?

No, not directly. Generics must meet the same regulatory standards for safety, purity, and effectiveness as brand-name drugs. However, when prices are cut too aggressively, some manufacturers may exit the market or reduce quality controls to stay profitable. This can lead to supply shortages or inconsistent availability, which patients may mistake for lower quality. Studies show that well-designed IRP systems with balanced reference baskets maintain high availability rates-up to 97% in countries using 5-7 reference nations.

Why don’t all countries use international reference pricing?

Some countries avoid IRP because of risks: shortages, loss of manufacturer incentives, and complexity in managing reference baskets. The U.S. prefers market competition and negotiation. Canada lets provinces run their own systems. The U.S. also lacks a centralized pricing authority, making IRP hard to implement. Additionally, countries with small markets or limited data may find IRP impractical due to lack of reliable price information from reference nations.

Can international reference pricing lead to drug shortages?

Yes, especially when prices are set too low without considering manufacturing costs. Greece experienced shortages of 37% of its generic drugs between 2012 and 2015 after drastic IRP cuts. Portugal saw 22 products discontinued in 2019 because reimbursement prices fell below production costs. Experts warn that IRP must include safeguards-like allowing for cost-based adjustments for complex generics-to prevent supply disruptions.

Is international reference pricing used for brand-name drugs too?

Yes, but differently. Many countries use IRP for patented drugs to set price ceilings before they enter the market. However, for generics, IRP is usually combined with other tools like tendering, mandatory discounts, or internal reference pricing within therapeutic groups. The key difference: brand-name drugs are often priced based on innovation value, while generics are priced based on cost and comparability. Some countries, like Switzerland, use separate formulas for each.